A Study to Evaluate Metabolism, Excretion, and Mass Balance of [14C]Vapendavir

An Open-label, Single-dose Study To Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]Vapendavir in Healthy Male Subjects

The goal of this clinical trial is to assess how the body processes, breaks down and removes a new test medicine (vapendavir) from the body in healthy male participants.The main question it aims to answer is how the body handles the test medicine. In order to do that, the test medicine will be radiolabeled to track the test medicine in the body.

Healthy male participants who meet entry criteria will be admitted to the clinic for a duration of approximately 9 days (Day -1 to Day 8). Participants will be admitted in the evening on the day before dosing (Day -1). Participants will take a single oral dose of radiolabeled vapendavir on Day 1 and have samples collected and safety tests completed during various times throughout their stay in the the clinic. The safety tests will provide additional information on the safety and tolerability of the test medicine.

Study Overview

• Status: Completed
• Conditions: Healthy Males
• Intervention / Treatment: Drug: Vapendavir

• Study Type: Interventional
• Enrollment (Actual): 8
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United Kingdom
  • UK
    • Nottingham, UK, United Kingdom, NG11 6JS
      • Quotient Sciences

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Must provide written informed consent
• Must be willing and able to communicate and participate in the whole study
• Participants must demonstrate their ability to swallow 8 capsules
• Aged 30 to 65 years inclusive at the time of signing informed consent
• Must agree to adhere to the study contraception requirements
• Healthy male participants according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs, 12- lead ECG, and laboratory safety tests without any clinically significant abnormalities
• Body mass index (BMI) of 18.0 to 35.0 kg/m2 as measured at screening
• Must have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day)

Exclusion Criteria:

• Serious adverse reaction or serious hypersensitivity to any drug or formulation excipients
• Presence or history of clinically significant allergy requiring treatment, as judged by the investigator
• History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder, as judged by the investigator
• Acute diarrhea or constipation in the 7 days before the predicted Day 1
• Participants who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening
• Clinically significant abnormal laboratory values at screening as judged by the investigator
• Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) 1 and 2 antibody results
• Evidence of renal impairment at screening
• Participants who have received any IMP in a clinical research study within the 90 days prior to Day 1, or less than 5 elimination half-lives prior to Day 1, whichever is longer
• Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study
• Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood
• Participants who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than up to 3 g of paracetamol per day) in the 14 days before dosing
• History of any drug or alcohol abuse in the past 2 years
• Regular alcohol consumption >21 units per week (1 unit = 1⁄2 pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 = 125 mL glass of wine, depending on type)
• A confirmed positive alcohol breath test
• Current smokers and those who have smoked within the last 12 months
• Current users of e-cigarettes or nicotine replacement products and those who have used these products within the last 12 months
• A confirmed breath carbon monoxide reading of greater than 10 ppm
• Confirmed positive drugs of abuse test result
• Male participants with pregnant or lactating partners
• Participants who are, or are immediate family members of, a study site or sponsor or employee
• Failure to satisfy the investigator of fitness to participate for any other reason

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Open-label, non-randomized, single-dose of [14C]Vapendavir; Single oral dose of [14C]Vapendavir	Drug: Vapendavir; Single oral dose of [14C]vapendavir

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To determine the mass balance recovery after a single oral dose of carbon-14 ([14C])vapendavir.	Mass balance recovery of total radioactivity in all excreta (urine and feces): CumAe and Cum%Ae.	From enrollment until the mass balance criteria have been met (~ 8 days).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To determine the routes and rates of elimination of [14C]vapendavir.	Determination of routes and rates of elimination of [14C]vapendavir by Ae, %Ae, CumAe and Cum%Ae by interval.	From enrollment until the mass balance criteria have been met (~ 8 days).
To perform metabolite profiling and structural identification from plasma, urine and fecal samples.	Identification of the chemical structure of each metabolite accounting for greater than or equal to 10% of circulating radioactivity in plasma ("AUC pool"), and accounting for greater than or equal to 10% of the dose in urine (from urine pools) and feces (fecal homogenate pools) will be performed.	From enrollment until the mass balance criteria have been met (~ 8 days).
To identify the chemical structure of each metabolite accounting for more than 10% of circulating total radioactivity or accounting for 10% or more of the dose in excreta.	Identification of the chemical structure of each metabolite accounting for more than 10% by AUC of circulating total radioactivity or accounting for 10% or more of the dose in excreta.	From enrollment until the mass balance criteria have been met (~ 8 days).
To evaluate the extent of distribution of total radioactivity into blood cells.	Evaluation of whole blood: plasma concentration ratios for total radioactivity.	From enrollment until the mass balance criteria have been met (~ 8 days).
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.	Time prior to the first measurable concentration (Tlag)	From enrollment until the mass balance criteria have been met (~ 8 days).
To provide additional safety and tolerability information for vapendavir by assessing: incidence of adverse events (AEs), new physical examination findings and change from baseline for vital signs, electrocardiograms (ECGs), and laboratory safety tests.	Descriptive summaries for all safety data (AEs, vital signs, ECGs and safety laboratory assessments) will be provided.	From enrollment until the mass balance criteria have been met (~ 8 days).
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.	Time of maximum observed concentration (Tmax)	From enrollment until the mass balance criteria have been met (~ 8 days)
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.	Maximum observed concentration (Cmax)	From enrollment until the mass balance criteria have been met (~ 8 days)
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.	Area under the curve from time 0 to the time of last measurable concentration (AUC (0-last))	From enrollment until the mass balance criteria have been met (~ 8 days)
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.	Area under the curve from time 0 extrapolated to infinity (AUC (0-inf))	From enrollment until the mass balance criteria have been met (~ 8 days)
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.	Terminal elimination half-life (T1/2)	From enrollment until the mass balance criteria have been met (~ 8 days)
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.	First order rate constant associated with the terminal (log-linear) portion of the curve (Ke)	From enrollment until the mass balance criteria have been met (~ 8 days)
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.	Total body clearance calculated after a single extravascular administration where F (fraction of dose bioavailable) is unknown (CL/F)	From enrollment until the mass balance criteria have been met (~ 8 days)
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.	Area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the cure extrapolated to infinity (AUCextrap)	From enrollment until the mass balance criteria have been met (~ 8 days)
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.	Mean residence time from time 0 to time of the last measurable concentration (MRT(0-last))	From enrollment until the mass balance criteria have been met (~ 8 days)
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.	Mean residence time from time 0 to extrapolated to infinity (MRT(0-inf))	From enrollment until the mass balance criteria have been met (~ 8 days)
To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.	Apparent volume of distribution based on the terminal phase calculated using AUC(0-inf) after a single extravascular administration where F (fraction of dose bioavailable) is unknown (Vd/F).	From enrollment until the mass balance criteria have been met (~ 8 days).

Collaborators and Investigators

• Sponsor: Altesa Biosciences, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): March 12, 2025
• Primary Completion (Actual): March 23, 2025
• Study Completion (Actual): March 23, 2025

Study Registration Dates

• First Submitted: February 11, 2025
• First Submitted That Met QC Criteria: February 14, 2025
• First Posted (Actual): February 19, 2025

Study Record Updates

• Last Update Posted (Actual): May 28, 2025
• Last Update Submitted That Met QC Criteria: May 22, 2025
• Last Verified: May 1, 2025

More Information

Terms related to this study

• Keywords: ADME Study in Healthy Males
• Other Study ID Numbers: ALT VPV-102

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No